Meeting
2019 ASCO Annual Meeting
Safety results of a phase III randomized trial of comparison of three paclitaxel-based regimens concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma (ESO-Shanghai 2).
Authors
Dashan Ai
Fudan University Shanghai Cancer Center, Shanghai, China
Dashan Ai , Yun Chen , Qi Liu , Xiangpeng Zheng , Yunhai Li , Shihong Wei , Jinjun Ye , Jialiang Zhou , Qin Lin , Hui Luo , Jianzhong Cao , Jiancheng Li , Guang Huang , Kailiang Wu , Min Fan , Huanjun Yang , Zhengfei Zhu , Weixin Zhao , Ling Li , Kuaile Zhao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT02459457
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4055)
DOI
10.1200/JCO.2019.37.15_suppl.4055
Abstract #
4055
Poster Bd #
160
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Final results of a phase III randomized trial of comparison of three paclitaxel-based regimens concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma.
First Author: Dashan Ai
Poster
2019 ASCO Annual Meeting
A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC).
First Author: Jian-Ming Xu
Poster
2018 ASCO Annual Meeting
Final results of a phase 3 study of comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in chemoradiotherapy for locally advanced esophageal carcinoma (ESO-Shanghai 1).
First Author: Yun Chen
Poster
2013 ASCO Annual Meeting
Induction chemotherapy (CT) with docetaxel, cisplatin, and fluorouracil (TPF) followed by concomitant cisplatin plus radiotherapy in locally advanced nasopharyngeal cancer (NPC): Results after 06 years.
First Author: Esma Kerboua